loading
Schlusskurs vom Vortag:
$7.89
Offen:
$7.82
24-Stunden-Volumen:
1.48M
Relative Volume:
0.85
Marktkapitalisierung:
$920.16M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-29.07M
KGV:
-27.05
EPS:
-0.29
Netto-Cashflow:
$-31.85M
1W Leistung:
+15.12%
1M Leistung:
+36.47%
6M Leistung:
+101.39%
1J Leistung:
+165.13%
1-Tages-Spanne:
Value
$7.74
$7.99
1-Wochen-Bereich:
Value
$6.67
$8.11
52-Wochen-Spanne:
Value
$2.36
$8.11

Trevi Therapeutics Inc Stock (TRVI) Company Profile

Name
Firmenname
Trevi Therapeutics Inc
Name
Telefon
203-304-2499
Name
Adresse
195 CHURCH STREET, NEW HAVEN, CT
Name
Mitarbeiter
31
Name
Twitter
@TreviThera
Name
Nächster Verdiensttermin
2025-03-18
Name
Neueste SEC-Einreichungen
Name
TRVI's Discussions on Twitter

Vergleichen Sie TRVI mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
TRVI
Trevi Therapeutics Inc
7.845 852.28M 0 -29.07M -31.85M -0.29
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
475.19 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
571.92 60.56B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
331.46 42.41B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
589.03 34.96B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.04 31.99B 3.81B -644.79M -669.77M -6.24

Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-07-01 Eingeleitet Cantor Fitzgerald Overweight
2025-05-28 Eingeleitet H.C. Wainwright Buy
2025-03-10 Bestätigt Needham Buy
2025-03-10 Hochstufung Raymond James Outperform → Strong Buy
2024-12-12 Bestätigt H.C. Wainwright Buy
2024-09-09 Fortgesetzt Leerink Partners Outperform
2024-08-30 Eingeleitet H.C. Wainwright Buy
2024-08-30 Eingeleitet Raymond James Outperform
2024-06-13 Eingeleitet Rodman & Renshaw Buy
2023-04-12 Eingeleitet B. Riley Securities Buy
2022-11-22 Eingeleitet SVB Leerink Outperform
2019-06-03 Eingeleitet BMO Capital Markets Outperform
2019-06-03 Eingeleitet Needham Buy
2019-06-03 Eingeleitet SVB Leerink Outperform
2019-06-03 Eingeleitet Stifel Buy
Alle ansehen

Trevi Therapeutics Inc Aktie (TRVI) Neueste Nachrichten

pulisher
Jul 23, 2025

Is Trevi Therapeutics Inc. a good long term investmentHigh-yield trading alerts - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

What drives Trevi Therapeutics Inc. stock priceRapid market gains - Autocar Professional

Jul 23, 2025
pulisher
Jul 23, 2025

The Business Case For Buying Trevi Therapeutics Inc (NASDAQ: TRVI) Stock Now - Stocksregister

Jul 23, 2025
pulisher
Jul 23, 2025

Trevi Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference - Seeking Alpha

Jul 23, 2025
pulisher
Jul 23, 2025

What analysts say about Trevi Therapeutics Inc. stockPhenomenal capital gains - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

Trevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and Metabolism - Eastern Progress

Jul 22, 2025
pulisher
Jul 22, 2025

How Trevi Therapeutics Inc. stock performs during market volatilityFree Access to Investors Club - Newser

Jul 22, 2025
pulisher
Jul 21, 2025

Trevi Therapeutics Inc. Stock Analysis and ForecastSuperior stock selection - Autocar Professional

Jul 21, 2025
pulisher
Jul 16, 2025

Trevi Therapeutics, Inc.'s (NASDAQ:TRVI) high institutional ownership speaks for itself as stock continues to impress, up 17% over last week - simplywall.st

Jul 16, 2025
pulisher
Jul 15, 2025

Why Trevi Therapeutics Inc. stock attracts strong analyst attentionSolid Return Trade Selections - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Trevi Therapeutics Inc. stock price move sharplyFree Smart Investment Opportunities - Newser

Jul 15, 2025
pulisher
Jul 13, 2025

Trevi Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering Use of Haduvio™ (nalbuphine ER) for the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis - The Globe and Mail

Jul 13, 2025
pulisher
Jul 11, 2025

Trevi Therapeutics (TRVI) Price Target Predicts 231.05% Upside Potential - AInvest

Jul 11, 2025
pulisher
Jul 11, 2025

Wall Street Analysts Predict a 231.05% Upside in Trevi Therapeutics (TRVI): Here's What You Should Know - Yahoo Finance

Jul 11, 2025
pulisher
Jul 09, 2025

31,359 Shares in Trevi Therapeutics, Inc. (NASDAQ:TRVI) Purchased by Vontobel Holding Ltd. - Defense World

Jul 09, 2025
pulisher
Jul 04, 2025

Cantor Fitzgerald Comments on TRVI FY2025 Earnings - Defense World

Jul 04, 2025
pulisher
Jul 01, 2025

Trevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and Metabolism | TRVI Stock News - GuruFocus

Jul 01, 2025
pulisher
Jul 01, 2025

Trevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and Metabolism. - AInvest

Jul 01, 2025
pulisher
Jun 30, 2025

Trevi Therapeutics, Inc.(NasdaqGM: TRVI) dropped from Russell 3000 Value Index - MarketScreener

Jun 30, 2025
pulisher
Jun 28, 2025

Cough in Idiopathic Pulmonary Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Algernon Pharma, Seyltx, Melius Pharma, NeRRe Therapeutics, Trevi Therapeutics - Barchart.com

Jun 28, 2025
pulisher
Jun 26, 2025

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Given Consensus Recommendation of “Buy” by Analysts - Defense World

Jun 26, 2025
pulisher
Jun 17, 2025

Trevi Therapeutics Stockholders Approve Key Amendments - TipRanks

Jun 17, 2025
pulisher
Jun 14, 2025

Leerink Partnrs Issues Optimistic Estimate for TRVI Earnings - Defense World

Jun 14, 2025
pulisher
Jun 12, 2025

Oppenheimer Raises Price Target for Trevi Therapeutics by $3 - MSN

Jun 12, 2025
pulisher
Jun 11, 2025

Squarepoint Ops LLC Acquires Shares of 14,059 Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World

Jun 11, 2025
pulisher
Jun 09, 2025

Trevi Therapeutics Announces Closing of $115 Million Underwritten Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares - Eastern Progress

Jun 09, 2025
pulisher
Jun 09, 2025

WilmerHale Advises Trevi Therapeutics, Inc. in $115 Million Public Offering - WilmerHale

Jun 09, 2025
pulisher
Jun 09, 2025

Two Sigma Advisers LP Invests $66,000 in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World

Jun 09, 2025
pulisher
Jun 09, 2025

Two Sigma Investments LP Purchases New Shares in Trevi Therapeutics, Inc. (NASDAQ:TRVI) - Defense World

Jun 09, 2025
pulisher
Jun 08, 2025

Trevi Therapeutics (NASDAQ:TRVI) Rating Lowered to “Sell” at Wall Street Zen - Defense World

Jun 08, 2025
pulisher
Jun 07, 2025

Trevi Therapeutics, Inc. (NASDAQ:TRVI) Shares Purchased by Millennium Management LLC - Defense World

Jun 07, 2025
pulisher
Jun 05, 2025

Finance Watch: Vera Raises Debt, Taysha And Trevi Price Offering After Big Trial Wins - insights.citeline.com

Jun 05, 2025
pulisher
Jun 05, 2025

Trevi Therapeutics Closes Public Offering - MarketScreener

Jun 05, 2025

Finanzdaten der Trevi Therapeutics Inc-Aktie (TRVI)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Trevi Therapeutics Inc-Aktie (TRVI) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
SCIASCIA THOMAS
Chief Scientific Officer
Mar 25 '25
Sale
6.60
2,631
17,365
221,373
GOOD JENNIFER L
President & CEO
Mar 21 '25
Option Exercise
1.43
5,263
7,526
218,576
GOOD JENNIFER L
President & CEO
Mar 21 '25
Sale
6.58
5,263
34,625
213,313
$23.62
price up icon 3.26%
$36.56
price up icon 1.51%
$103.38
price down icon 0.14%
$27.57
price down icon 1.58%
$114.12
price down icon 0.42%
biotechnology ONC
$296.06
price up icon 0.42%
Kapitalisierung:     |  Volumen (24h):